Antelope Therapeutics is a preclinical-stage oncology company developing ATL-024, a novel Antibody-Drug Conjugate (ADC) against a first-in-class target for the treatment of colorectal and pancreatic cancers. These two diseases cause nearly 400,000 deaths annually across the 7MM and represent a multi-billion-dollar market opportunity.

Founded by ADC experts, including the former co-founder and CSO, and the former CBO of Mablink Bioscience (acquired by Eli Lilly), Antelope has identified CA242, a target with high expression prevalence across CRC and PDAC, representing 240,000+ patients annually, while being absent from healthy tissues.

ATL-024 combines a clinically de-risked antibody with an innovative proprietary linker platform and a topoisomerase I inhibitor payload to address this target. Preclinical studies have demonstrated compelling efficacy across multiple tumor models and an outstanding tolerability profile in NHP, supporting its best-in-disease potential.

Antelope is targeting clinical entry in 2027 and is seeking investors and partners to accelerate the development of ATL-024, including financing, licensing, and broader strategic discussions.